



Flavivaccine

Safely protecting against
mosquito-borne viral diseases



We aim to deliver a **safe and cost-effective** vaccine against diseases resulting from mosquito-borne flavivirus infections, such as dengue, yellow fever, Zika and West Nile viruses.

RISING MOSQUITO-BORNE PANDEMIC THREATS DUE TO CLIMATE CHANGE AND HUMAN-LED ENVIRONMENTAL IMPACT

- **500 mil** Infections per year
- **>100.000** Annual deaths
- **€9 bil** Economic loss (For dengue virus only)

■ 1 Flavivaccine

Our novel approach enables the **targeting of multiple flaviviruses with a single vaccine**, thereby **lifting the burden from healthcare systems**. This solution has **multi-market potential**, serving both as a **travel and epidemic/pandemic response strategy**.

FIND OUT MORE



EMAIL

INFO@FLAVIVACCINE.COM

PROJECT
COORDINATOR

Mr. Julien Pompon - IRD

JULIEN.POMPON@IRD.FR



[Flavivaccine](#)



[@Flavivaccine](#)



Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.